Gastric Cancer Biomarkers Identified in New Study
A new research study identifies lncRNAs CBR3-AS1 and PCA3 as significantly overexpressed in gastric cancer tissues.
A new research study identifies lncRNAs CBR3-AS1 and PCA3 as significantly overexpressed in gastric cancer tissues.
Researchers developed a urine-based diagnostic kit for bladder cancer, offering a solution for early detection and monitoring at home.
Lucid Diagnostics secured a patent allowance for its proprietary method of using CCNA1 gene methylation to detect esophageal cancer.
Thermo Fisher’s SeCore CDx HLA A Sequencing System received FDA clearance as a CDx for TECELRA, a T-cell receptor therapy from Adaptimmune.
Read MoreA blood test measuring lymphocyte levels may predict the effectiveness of CAR-T immunotherapy in relapsed multiple myeloma patients.
Read MoreA new machine-learning serum fusion-gene model shows promise in increasing hepatocellular carcinoma diagnostic accuracy and monitoring.
Read MoreResearcher identified a 15-gene signature biomarker that can stratify renal cancer patients into low or high risk of recurrence.
Read MoreA new genotyping test using cerebrospinal fluid can rapidly diagnose brain cancers, reducing the need for invasive biopsies.
Read MoreResearchers discovered a novel immune-based biomarker that could pave the way for potential early detection of high-grade ovarian cancer.
Read MoreA clinical trial shows that a Helio Genomics test outperforms ultrasound in detecting hepatocellular carcinoma in liver cirrhosis patients.
Read MoreSalignostics has partnered with ARC Innovation at Sheba Medical Center to develop a saliva-based test for detecting oral cavity cancer.
Read MoreMercy BioAnalytics will present data showing that their Mercy Halo test significantly improves early detection of ovarian cancer.
Read MoreResearchers discovered new biomarkers for renal cell carcinomas, enhancing the diagnosis of various subtypes.
Read MoreThe tumor cell enumeration assay is a diagnostic test that is promising for establishing the diagnosis of leptomeningeal metastases.
Read MoreThe U.S. Patent and Trademark Office issued a patent to Myriad Genetics aimed at strengthening its ability to deliver a MRD assay to market.Â
Read MoreA new algorithm may help identify high-risk precancerous lesions on the fallopian tubes thought to lead to a common form of ovarian cancer
Read MoreThe Oncuria Bladder Cancer Tests, a DiaCarta validated lab developed test (LDT), received Medicare coverage effective Jan. 1, 2024.
Read MoreResearchers have developed a new biosensor using terahertz waves that can detect skin cancer with improved sensitivity.
Read More